PubRank

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

Clinical Trial ID NCT01417000

PubWeight™ 16.42‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01417000

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015 2.98
2 Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008 2.67
3 Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004 2.27
4 Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012 1.47
5 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
6 Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov 2015 1.18
7 Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol 2014 1.13
8 Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 2013 1.00
9 Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol 2014 0.95
10 Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol 2012 0.95
11 From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016 0.90
12 A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther 2013 0.88
13 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
14 Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012 0.80
15 Bacterial vectors for active immunotherapy reach clinical and industrial stages. Hum Vaccin Immunother 2012 0.78
16 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
17 The Promise of Preventive Cancer Vaccines. Vaccines (Basel) 2015 0.77
Next 100